Transcatheter mitral valve repair: a paradigm shift in mitral regurgitation treatment

Mitral regurgitation (MR) is the most prevalent valvular heart disease in developed countries, particularly affecting the elderly population. In its severe, untreated form, MR is associated with high morbidity and mortality. Current therapeutic approaches include pharmacological management, surgical interventions, and emerging transcatheter mitral valve repair (TMVR) techniques. While medical therapy provides symptomatic relief, it lacks disease-modifying effects in advanced cases. Surgical repair or replacement remains the gold standard; however, it is often unsuitable for high-risk or inoperable patients. TMVR has emerged as a transformative, minimally invasive alternative, offering improved outcomes with reduced procedural risks. Devices such as MitraClip, Cardio band, and other novel TMVR technologies have demonstrated encouraging results in clinical trials, improving survival rates and quality of life. Despite its advantages, challenges such as anatomical variability, device durability, and long-term efficacy remain. With continuous technological advancements, optimized patient selection, and collaborative efforts in research and innovation, TMVR is poised to revolutionize the management of MR, bridging the gap between conventional surgery and medical therapy. This editorial explores the current landscape, benefits, limitations, and future directions of TMVR in the treatment of MR.